
美国食品药品监督管理局(FDA)周一宣布,要求GLP-1类药物生产商警告此类药物可能增加视力丧失风险。该机构要求GLP-1生产商警告药物可能增加“眼中风”风险。
The agency is requiring GLP-1 manufacturers to warn the drugs can increase risk of “eye stroke.”The Food and Drug Administration announced Monday that it is requiring manufacturers of GLP-1 medications to warn that they can increase the risk of vision loss.
这一警告适用于所有GLP-1药物,包括Ozempic和Wegovy等热门减肥药。
The warning applies to all GLP-1 medications, including popular weight loss drugs like Ozempic and Wegovy.
FDA表示,GLP-1药物可能导致非动脉炎性前部缺血性视神经病变(NAION),这是一种非常罕见的疾病,视神经供血不足会导致单眼视力下降或视力丧失。
GLP-1s can lead to cases of non-arteritic anterior ischemic optic neuropathy (NAION), a very rare condition where a lack of blood flow to the optic nerve causes decreased vision or vision loss in an eye, the agency said.
NAION目前尚无已知的治疗方法,该病还与糖尿病、吸烟和高血压有关。
There is no known treatment for NAION, which is also associated with diabetes, smoking and high blood pressure.
关于GLP-1药物是否会增加NAION(常被称为“眼中风”)风险,各项研究得出的结论相互矛盾,但相关诉讼和一些研究结果已引发人们对这类药物可能带来副作用的担忧。
Studies have reached conflicting conclusions about whether GLP-1 drugs raise the risk of NAION, often referred to as “eye stroke,” but lawsuits and some findings have raised concerns about side effects the drugs may carry.
FDA援引2024年一项针对约1.6万名眼科患者的研究称,该研究发现司美格鲁肽与NAION之间存在关联,但并未确立两者之间的因果关系。司美格鲁肽是人体天然GLP-1的合成版本,可调节血糖并传递饱腹信号。
The FDA cited a 2024 study of about 16,000 ophthalmology patients that found an association between semaglutide — synthetic versions of the body’s naturally occurring GLP-1 that regulate blood sugar and signal fullness — and NAION but did not establish a causal relationship between the two.
多起诉讼指控患者在使用GLP-1药物后患上NAION并出现视力丧失。FDA在公告中表示,其结论是基于对临床试验数据、观察性研究和病例报告的审查得出的。
Numerous lawsuits have alleged that patients suffered NAION and vision loss after using GLP-1s. The FDA said in its announcement that it reviewed clinical trial data, observational studies and case reports to make its conclusion.
FDA表示,目前市场上所有GLP-1产品均有NAION病例报告。
NAION cases have been reported for all currently marketed GLP-1 products, the FDA said.
减肥药生产商礼来公司在声明中表示,正在评估这一更新,并将尽快回应FDA。
Eli Lilly, which manufactures weight loss drugs, said in a statement that it is evaluating the update and will respond to the FDA promptly.
“患者安全是礼来的首要任务,”该公司表示。“美国食品药品监督管理局(FDA)的药物安全通报适用于所有具有GLP-1受体激动剂活性的药物,并未提及任何针对礼来药物的具体发现。”同样生产FDA批准的GLP-1药物的诺和诺德和赛诺菲,周一午后未立即回应置评请求。
“Patient safety is Lilly’s top priority,” the company said. “FDA’s drug safety communication applies to all medicines with GLP-1 RA activity and does not reference any findings specific to Lilly medicines.”Novo Nordisk and Sanofi, which also manufacture FDA-approved GLP-1 medications, did not immediately respond to a request for comment Monday afternoon.
诺和诺德在周一公告发布前向《华盛顿邮报》发表声明称,针对该公司的个人伤害诉讼“毫无依据”,并且一项2026年针对该公司GLP-1产品临床试验逾9万名参与者的研究发现,这些药物与NAION之间没有关联。
Novo Nordisk said in a statement to The Washington Post before Monday’s announcement that personal injury lawsuits against the company are “without merit” and that a 2026 study of over 90,000 participants in clinical trials for the company’s GLP-1 products found no association between the drugs and NAION.
“考虑到来自临床试验、上市后报告和观察性研究的全部证据,加之NAION的发病率总体较低,诺和诺德认为司美格鲁肽的获益-风险特征仍然有利,”诺和诺德发言人莉兹·斯克尔布科娃表示。
“Considering the totality of evidence from clinical trials, post-marketing reports and observational studies, alongside the generally low incidence rate of NAION, Novo believes that the benefit-risk profile of semaglutide remains favorable,” Novo Nordisk spokesperson Liz Skrbkova said.
FDA表示,患者如果出现NAION症状,应立即联系医生,并讨论是继续服用GLP-1药物还是停药。
Patients should contact their doctors immediately if they experience symptoms of NAION and discuss whether to continue taking GLP-1s or stop, the FDA said.